Symbol="ATRA"
AssetType="Common Stock"
Name="Atara Biotherapeutics Inc"
Description="Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California."
CIK="1604464"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="143565000"
EBITDA="-295590016"
PERatio="None"
PEGRatio="0"
BookValue="0.074"
DividendPerShare="0"
DividendYield="0"
EPS="-3.16"
RevenuePerShareTTM="0.066"
ProfitMargin="0"
OperatingMarginTTM="-43.8"
ReturnOnAssetsTTM="-0.551"
ReturnOnEquityTTM="-2.299"
RevenueTTM="6863000"
GrossProfitTTM="63573000"
DilutedEPSTTM="-3.16"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.981"
AnalystTargetPrice="14.72"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.538"
PriceToBookRatio="1.967"
EVToRevenue="2.31"
EVToEBITDA="-0.562"
Beta="0.991"
num_52WeekHigh="5.64"
num_52WeekLow="1.25"
num_50DayMovingAverage="1.9"
num_200DayMovingAverage="3.051"
SharesOutstanding="101102000"
DividendDate="None"
ExDividendDate="None"
symbol="ATRA"
open="1.47"
high="1.49"
low="1.40"
price="1.42"
volume="2558430.00"
latest_trading_day="2023-08-25"
previous_close="1.50"
change="-0.08"
change_percent="-5.3333%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="90"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="10"
Volume_recent_avg="1689466"
Change_recent_avg="-0.01"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.88"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="10"
Aroon_momentum_negative="90"
image_negative_thumbnail_id_1="1086"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0119.jpeg"
image_negative_thumbnail_id_2="122"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0054.jpeg"
image_neutral_thumbnail_id_1="432"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="556"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0043.jpeg"
image_positive_thumbnail_id_1="641"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0067.jpeg"
image_positive_thumbnail_id_2="983"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0145.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1173"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
